Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DVAX Dynavax Technologies	$10.72 +0.5%	$10.10	$9.22 ▼ $14.63	$1.29B	1.03	2.15 million shs	928,420 shs
GPCR Structure Therapeutics	$19.25 -1.4%	$21.73	$13.22 ▼ $45.37	$1.10B	-1.87	818,828 shs	1.64 million shs
HRMY Harmony Biosciences	$35.20 -3.4%	$33.84	$26.47 ▼ $41.61	$2.02B	0.83	636,888 shs	701,636 shs
SDGR Schrodinger	$21.45 -0.9%	$21.94	$16.60 ▼ $28.47	$1.57B	1.58	928,386 shs	962,275 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DVAX Dynavax Technologies	0.00%	+1.32%	+4.08%	+4.11%	+0.47%
GPCR Structure Therapeutics	0.00%	+1.26%	-10.96%	-11.53%	-49.79%
HRMY Harmony Biosciences	0.00%	+3.53%	+8.37%	+23.68%	+6.41%
SDGR Schrodinger	0.00%	+2.09%	+1.90%	-16.70%	-7.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DVAX Dynavax Technologies	4.4209 of 5 stars	3.3	2.0	4.7	2.7	1.7	1.9
GPCR Structure Therapeutics	2.9663 of 5 stars	3.5	3.0	0.0	3.0	1.7	0.6
HRMY Harmony Biosciences	4.8291 of 5 stars	4.5	1.0	0.0	3.9	3.3	4.4
SDGR Schrodinger	2.0363 of 5 stars	3.4	1.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	123.88% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	295.67% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.33	45.83% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	52.68% Upside

Current Analyst Ratings Breakdown

Latest GPCR, SDGR, HRMY, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$33.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DVAX Dynavax Technologies	$277.25M	4.64	$0.16 per share	67.70	$4.54 per share	2.36
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
HRMY Harmony Biosciences	$744.85M	2.71	$2.95 per share	11.95	$11.56 per share	3.04
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	21.88	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	13.44	11.32	0.48	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)

Latest GPCR, SDGR, HRMY, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	N/A	N/A	N/A	$87.55 million	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	N/A	N/A	N/A	$204.37 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DVAX Dynavax Technologies	0.49	11.93	10.84
GPCR Structure Therapeutics	N/A	23.29	23.29
HRMY Harmony Biosciences	0.22	3.67	3.63
SDGR Schrodinger	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DVAX Dynavax Technologies	96.96%
GPCR Structure Therapeutics	91.78%
HRMY Harmony Biosciences	86.23%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
DVAX Dynavax Technologies	2.98%
GPCR Structure Therapeutics	9.43%
HRMY Harmony Biosciences	23.60%
SDGR Schrodinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable

GPCR, SDGR, HRMY, and DVAX Headlines

Recent News About These Companies

Comparing Schrodinger (NASDAQ:SDGR) & Strata Skin Sciences (NASDAQ:SSKN)

July 20 at 2:41 AM | americanbankingnews.com

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

July 18 at 10:25 AM | globenewswire.com

Massachusetts Financial Services Co. MA Sells 186,228 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 18 at 5:38 AM | marketbeat.com

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17 at 10:30 AM | finance.yahoo.com

Schrodinger (NASDAQ:SDGR) Given New $30.00 Price Target at KeyCorp

July 15, 2025 | americanbankingnews.com

KeyCorp Has Lowered Expectations for Schrodinger (NASDAQ:SDGR) Stock Price

July 14, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Position Raised by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

BMO Capital Remains a Buy on Schrodinger (SDGR)

July 11, 2025 | theglobeandmail.com

Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock

July 10, 2025 | finance.yahoo.com

Allspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

July 7, 2025 | marketbeat.com

SDGR - Schrodinger Inc Ordinary Shares Financials - Morningstar

July 5, 2025 | morningstar.comM

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

July 3, 2025 | investing.com

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

July 3, 2025 | msn.com

Morgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)

July 3, 2025 | marketbeat.com

Schrödinger, Inc. (SDGR) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

July 2, 2025 | prnewswire.com

Short SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term target

July 1, 2025 | invezz.comI

Sumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 1, 2025 | marketbeat.com

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27, 2025 | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 23, 2025 | globenewswire.com

17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLC

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, SDGR, HRMY, and DVAX Company Descriptions

Dynavax Technologies NASDAQ:DVAX

$10.72 +0.05 (+0.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$10.90 +0.18 (+1.72%)

As of 07/18/2025 07:58 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Structure Therapeutics NASDAQ:GPCR

$19.25 -0.28 (-1.43%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$19.21 -0.04 (-0.20%)

As of 07/18/2025 06:52 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Harmony Biosciences NASDAQ:HRMY

$35.20 -1.23 (-3.38%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$35.48 +0.28 (+0.80%)

As of 07/18/2025 07:10 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Schrodinger NASDAQ:SDGR

$21.45 -0.20 (-0.92%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.74 +0.29 (+1.33%)

As of 07/18/2025 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time